Hepatocyte growth factor receptor
Homo sapiens
State in the Current Structure
| Assembly | Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Associated Components | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|
| 1 | Protein monomer Monomer Protein × 1 PDB declaration: monomeric（1） Consistent with protein copy count | Chain A； UniProt 1049–1360 | Fragment：tyrosine kinase domain, residues in UNP 1049-1360 Mutation：Y1194F,Y1234F,Y1235D | CL CHLORIDE ION × 1 IPA ISOPROPYL ALCOHOL × 2 DFQ (2E)-3-{6-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]quinolin-3-yl}-N-methylprop-2-enamide × 1 | X-RAY DIFFRACTION X-ray crystallization conditions：VAPOR DIFFUSION, HANGING DROP；pH 7.5；285 K；14%(w/v) PEG MME 5000, 5%(v/v) isopropanol, 12%(v/v) MPD, 0.1M Tris-Cl, 15%(v/v) Glycerol, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 285K | Resolution 2.54 Å R-free 0.240 |
Other States of the Same Protein in the Database
Each row is a biological assembly of the same UniProt protein in another PDB entry. The “Difference from current entry” column identifies evidence-level differences; no tag means the currently parsed fields agree.
| Other PDB | Difference from Current Entry 3A4P | Assembly / Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Non-polymers | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|---|
| 11HQ Type-III c-MET Inhibitor Enabled by Free-Energy Perturbation Calculations Deposited 2026-02-25 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1037–1346（310 aa）
|
Mutation：L1272V | A1C9B (1R,6M)-1-benzyl-6-[(3P)-3-(1-ethyl-1H-pyrazol-4-yl)-5-fluorophenyl]-1,2-dihydro-3H-pyrrolo[3,4-c]pyridin-3-one × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.1 M HEPES pH 6.5, 10% PEG 6000, 5% MPD
|
Resolution 2.65 Å R-free 0.287 |
| 11HQ Type-III c-MET Inhibitor Enabled by Free-Energy Perturbation Calculations Deposited 2026-02-25 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
1037–1346（310 aa）
|
Mutation：L1272V | A1C9B (1R,6M)-1-benzyl-6-[(3P)-3-(1-ethyl-1H-pyrazol-4-yl)-5-fluorophenyl]-1,2-dihydro-3H-pyrrolo[3,4-c]pyridin-3-one × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.1 M HEPES pH 6.5, 10% PEG 6000, 5% MPD
|
Resolution 2.65 Å R-free 0.287 |
| 11HQ Type-III c-MET Inhibitor Enabled by Free-Energy Perturbation Calculations Deposited 2026-02-25 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain C
1037–1346（310 aa）
|
Mutation：L1272V | A1C9B (1R,6M)-1-benzyl-6-[(3P)-3-(1-ethyl-1H-pyrazol-4-yl)-5-fluorophenyl]-1,2-dihydro-3H-pyrrolo[3,4-c]pyridin-3-one × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.1 M HEPES pH 6.5, 10% PEG 6000, 5% MPD
|
Resolution 2.65 Å R-free 0.287 |
| 1FYR DIMER FORMATION THROUGH DOMAIN SWAPPING IN THE CRYSTAL STRUCTURE OF THE GRB2-SH2 AC-PYVNV COMPLEX Deposited 2000-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain I
1356–1359（4 aa）
Fragment：RESIDUES 1356-1359 (RESIDUES 0-3 IN COORDINATES)
Chain J
1356–1359（4 aa）
Fragment：RESIDUES 1356-1359 (RESIDUES 0-3 IN COORDINATES)
|
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.7；298 K；11% PEG 3350, 0.5M NaCL, 0.1M MES/NaOH pH 5.7, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.40 Å R-free 0.270 |
| 1FYR DIMER FORMATION THROUGH DOMAIN SWAPPING IN THE CRYSTAL STRUCTURE OF THE GRB2-SH2 AC-PYVNV COMPLEX Deposited 2000-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain K
1356–1359（4 aa）
Fragment：RESIDUES 1356-1359 (RESIDUES 0-3 IN COORDINATES)
Chain L
1356–1359（4 aa）
Fragment：RESIDUES 1356-1359 (RESIDUES 0-3 IN COORDINATES)
|
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.7；298 K；11% PEG 3350, 0.5M NaCL, 0.1M MES/NaOH pH 5.7, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.40 Å R-free 0.270 |
| 1FYR DIMER FORMATION THROUGH DOMAIN SWAPPING IN THE CRYSTAL STRUCTURE OF THE GRB2-SH2 AC-PYVNV COMPLEX Deposited 2000-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain I
1356–1359（4 aa）
Fragment：RESIDUES 1356-1359 (RESIDUES 0-3 IN COORDINATES)
Chain J
1356–1359（4 aa）
Fragment：RESIDUES 1356-1359 (RESIDUES 0-3 IN COORDINATES)
Chain K
1356–1359（4 aa）
Fragment：RESIDUES 1356-1359 (RESIDUES 0-3 IN COORDINATES)
Chain L
1356–1359（4 aa）
Fragment：RESIDUES 1356-1359 (RESIDUES 0-3 IN COORDINATES)
|
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.7；298 K；11% PEG 3350, 0.5M NaCL, 0.1M MES/NaOH pH 5.7, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.40 Å R-free 0.270 |
| 1FYR DIMER FORMATION THROUGH DOMAIN SWAPPING IN THE CRYSTAL STRUCTURE OF THE GRB2-SH2 AC-PYVNV COMPLEX Deposited 2000-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 4 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain I
1356–1359（4 aa）
Fragment：RESIDUES 1356-1359 (RESIDUES 0-3 IN COORDINATES)
Chain J
1356–1359（4 aa）
Fragment：RESIDUES 1356-1359 (RESIDUES 0-3 IN COORDINATES)
Chain K
1356–1359（4 aa）
Fragment：RESIDUES 1356-1359 (RESIDUES 0-3 IN COORDINATES)
Chain L
1356–1359（4 aa）
Fragment：RESIDUES 1356-1359 (RESIDUES 0-3 IN COORDINATES)
|
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.7；298 K；11% PEG 3350, 0.5M NaCL, 0.1M MES/NaOH pH 5.7, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.40 Å R-free 0.270 |
| 1FYR DIMER FORMATION THROUGH DOMAIN SWAPPING IN THE CRYSTAL STRUCTURE OF THE GRB2-SH2 AC-PYVNV COMPLEX Deposited 2000-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 5 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric |
Chain I
1356–1359（4 aa）
Fragment：RESIDUES 1356-1359 (RESIDUES 0-3 IN COORDINATES)
Chain J
1356–1359（4 aa）
Fragment：RESIDUES 1356-1359 (RESIDUES 0-3 IN COORDINATES)
Chain K
1356–1359（4 aa）
Fragment：RESIDUES 1356-1359 (RESIDUES 0-3 IN COORDINATES)
|
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.7；298 K；11% PEG 3350, 0.5M NaCL, 0.1M MES/NaOH pH 5.7, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.40 Å R-free 0.270 |
| 1FYR DIMER FORMATION THROUGH DOMAIN SWAPPING IN THE CRYSTAL STRUCTURE OF THE GRB2-SH2 AC-PYVNV COMPLEX Deposited 2000-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 6 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric |
Chain J
1356–1359（4 aa）
Fragment：RESIDUES 1356-1359 (RESIDUES 0-3 IN COORDINATES)
Chain K
1356–1359（4 aa）
Fragment：RESIDUES 1356-1359 (RESIDUES 0-3 IN COORDINATES)
Chain L
1356–1359（4 aa）
Fragment：RESIDUES 1356-1359 (RESIDUES 0-3 IN COORDINATES)
|
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.7；298 K；11% PEG 3350, 0.5M NaCL, 0.1M MES/NaOH pH 5.7, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.40 Å R-free 0.270 |
| 1R0P Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met in complex with the microbial alkaloid K-252a Deposited 2003-09-22 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1049–1360（312 aa）
Fragment：tyrosine kinase domain
|
Mutation：Y1194F, Y1234F, Y1235D, V1272L | KSA K-252A × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.1；277 K；PEG 5000 MME, isopropanol, Hepes, pH 7.1, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 1.80 Å R-free 0.197 |
| 1R1W CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET Deposited 2003-09-25 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1049–1360（312 aa）
Fragment：TYROSINE KINASE DOMAIN
|
Mutation：Y1194F, Y1234F, Y1235D, V1272L | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.1；277 K；PEG 5000 MME, isopropanol, Hepes, pH 7.10, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 1.80 Å R-free 0.204 |
| 1SHY The Crystal Structure of HGF beta-chain in Complex with the Sema Domain of the Met Receptor. Deposited 2004-02-26 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
25–567（543 aa）
Fragment：Met receptor Sema and PSI domain
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；292 K；PEG, pH 8, VAPOR DIFFUSION, HANGING DROP, temperature 292K
|
Resolution 3.22 Å R-free 0.270 |
| 1SSL Solution structure of the PSI domain from the Met receptor Deposited 2004-03-24 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
519–562（44 aa）
Fragment：PSI domain (residues 519-562)
|
Not recorded | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 6；283 K；Ionic strength (raw mmCIF value) 0.15M NaCl；Pressure ambient
NMR sample composition
1mM PSI, 50mM phosphate buffer, 0.15M NaC, 90%H2O, 10%D2O | 90% H2O/10% D2O
NMR sample composition
1mM PSI, 50mM phosphate buffer, 0.15M NaCl, 100%D2O | 100% D2O
|
Resolution not provided |
| 2RFN x-ray structure of c-Met with inhibitor. Deposited 2007-10-01 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1048–1351（304 aa）
Fragment：UNP residues 1048-1351
|
Not recorded | AM7 2-benzyl-5-(3-fluoro-4-{[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxy}phenyl)-3-methylpyrimidin-4(3H)-one × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 5；298 K；12% PEG 6000, 1.0M LiCl2, 0.1M sodium citrate, pH 5.0, VAPOR DIFFUSION, temperature 298K
|
Resolution 2.50 Å R-free 0.294 |
| 2RFN x-ray structure of c-Met with inhibitor. Deposited 2007-10-01 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
1048–1351（304 aa）
Fragment：UNP residues 1048-1351
|
Not recorded | AM7 2-benzyl-5-(3-fluoro-4-{[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxy}phenyl)-3-methylpyrimidin-4(3H)-one × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 5；298 K；12% PEG 6000, 1.0M LiCl2, 0.1M sodium citrate, pH 5.0, VAPOR DIFFUSION, temperature 298K
|
Resolution 2.50 Å R-free 0.294 |
| 2RFS X-ray structure of SU11274 bound to c-Met Deposited 2007-10-01 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1048–1351（304 aa）
Fragment：UNP residues 1048-1351
|
Not recorded | AM8 N-(3-chlorophenyl)-N-methyl-2-oxo-3-[(3,4,5-trimethyl-1H-pyrrol-2-yl)methyl]-2H-indole-5-sulfonamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7.8；298 K；0.1M HEPES pH 7.8, 15% PEG 4K, 6% 2-propanol, 40mM BME, 3% Ethanol, VAPOR DIFFUSION, temperature 298K
|
Resolution 2.20 Å R-free 0.262 |
| 2UZX Structure of the human receptor tyrosine kinase Met in complex with the Listeria monocytogenes invasion protein InlB: Crystal form I Deposited 2007-05-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
25–740（716 aa）
Fragment：SEMA, PSI, IG1, MET741, RESIDUES 25-740
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；293 K；20 DEG C VAPOR DIFFUSION. 2 UL PROTEIN (5 MG/ML) PLUS 1 UL RESERVOIR CONSISTING OF 16.5% PEG 1500, 4.4% MPD, 0.1 M TRIS, PH8.5. RESERVOIR WAS COVERED WITH ALS OIL.
|
Resolution 2.80 Å R-free 0.307 |
| 2UZX Structure of the human receptor tyrosine kinase Met in complex with the Listeria monocytogenes invasion protein InlB: Crystal form I Deposited 2007-05-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain D
25–740（716 aa）
Fragment：SEMA, PSI, IG1, MET741, RESIDUES 25-740
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；293 K；20 DEG C VAPOR DIFFUSION. 2 UL PROTEIN (5 MG/ML) PLUS 1 UL RESERVOIR CONSISTING OF 16.5% PEG 1500, 4.4% MPD, 0.1 M TRIS, PH8.5. RESERVOIR WAS COVERED WITH ALS OIL.
|
Resolution 2.80 Å R-free 0.307 |
| 2UZY Structure of the human receptor tyrosine kinase Met in complex with the Listeria monocytogenes invasion protein inlb: low resolution, Crystal form II Deposited 2007-05-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
25–740（716 aa）
Fragment：SEMA, PSI, IG1, IG2\: MET741, RESIDUES 25-740
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；VAPOR DIFFUSION AT 25 DEGREE C IN SITTING-DROPS. 2 UL PROTEIN (8 MG/ML)PLUS 2 UL RESERVOIR (1.4 M NA/K PHOSPHATE, PH 6.5, 10% PEG 2000 MONO-METHYL-ETHER)
|
Resolution 4.00 Å R-free 0.301 |
| 2UZY Structure of the human receptor tyrosine kinase Met in complex with the Listeria monocytogenes invasion protein inlb: low resolution, Crystal form II Deposited 2007-05-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain D
25–740（716 aa）
Fragment：SEMA, PSI, IG1, IG2\: MET741, RESIDUES 25-740
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；VAPOR DIFFUSION AT 25 DEGREE C IN SITTING-DROPS. 2 UL PROTEIN (8 MG/ML)PLUS 2 UL RESERVOIR (1.4 M NA/K PHOSPHATE, PH 6.5, 10% PEG 2000 MONO-METHYL-ETHER)
|
Resolution 4.00 Å R-free 0.301 |
| 2WD1 Human c-Met Kinase in complex with azaindole inhibitor Deposited 2009-03-19 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1055–1346（292 aa）
Fragment：KINASE DOMAIN, RESIDUES 1055-1346
|
Not recorded | ZZY 1-[(2-NITROPHENYL)SULFONYL]-1H-PYRROLO[3,2-B]PYRIDINE-6-CARBOXAMIDE × 1 GBL GAMMA-BUTYROLACTONE × 2 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.00 Å R-free 0.265 |
| 2WGJ X-ray Structure of PF-02341066 bound to the kinase domain of c-Met Deposited 2009-04-20 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1051–1348（298 aa）
Fragment：TYROSINE KINASE DOMAIN, RESIDUES 1051-1348
|
Not recorded | VGH 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-amine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.6；286 K；CRYSTALS WERE GROWN BY HANGING DROP VAPOR DIFFUSION AT 13 DEGREES CELCIUS. 1-2 MICROLITERS OF PROTEIN SOLUTION AT 7-15 MG/ML WAS MIXEDWITH AN EQUAL VOLUME OF PRECIPITATING SOLUTION (0-275 MM SODIUM CHLORIDE, 21% (W/V PEG 3350, 50 MM CITRATE-PHOSPHATE PH 4.6)
|
Resolution 2.00 Å R-free 0.232 |
| 2WKM X-ray Structure of PHA-00665752 bound to the kinase domain of c-Met Deposited 2009-06-15 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1051–1348（298 aa）
Fragment：TYROSINE KINASE DOMAIN, UNP RESIDUES 1051-1348
|
Not recorded | PFY (3Z)-5-[(2,6-DICHLOROBENZYL)SULFONYL]-3-[(3,5-DIMETHYL-4-{[(2S)-2-(PYRROLIDIN-1-YLMETHYL)PYRROLIDIN-1-YL]CARBONYL}-1H-PYRROL-2-YL)METHYLIDENE]-1,3-DIHYDRO-2H-INDOL-2-ONE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.6；286 K；CRYSTALS WERE OBTAINED AT 13 DEGREES C BY THE HANGING DROP VAPOR DIFFUSION METHOD USING 1.2 MICROLITERS OF PROTEIN SOLUTION (CONTAINING 7-13 MG/ML C-MET KD PLUS A 5 FOLD MOLAR EXCESS OF PHA-00665752) AND 1.2 MICROLITERS OF MOTHER LIQUOR SOLUTION (0.05 M CITRATE-PHOSHPHATE 4.6, 0-0.275 M NACL, AND 21% W/V PEG 3350).
|
Resolution 2.20 Å R-free 0.275 |
| 3BUX Crystal structure of c-Cbl-TKB domain complexed with its binding motif in c-Met Deposited 2008-01-03 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
997–1009（13 aa）
Fragment：UNP residues 997-1009, pTyr-1003 phosphopeptide
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；298 K；0.15M malic acid, 20% PEG 3350, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 1.35 Å R-free 0.240 |
| 3BUX Crystal structure of c-Cbl-TKB domain complexed with its binding motif in c-Met Deposited 2008-01-03 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain C
997–1009（13 aa）
Fragment：UNP residues 997-1009, pTyr-1003 phosphopeptide
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；298 K；0.15M malic acid, 20% PEG 3350, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 1.35 Å R-free 0.240 |
| 3BUX Crystal structure of c-Cbl-TKB domain complexed with its binding motif in c-Met Deposited 2008-01-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 5 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
997–1009（13 aa）
Fragment：UNP residues 997-1009, pTyr-1003 phosphopeptide
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；298 K；0.15M malic acid, 20% PEG 3350, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 1.35 Å R-free 0.240 |
| 3BUX Crystal structure of c-Cbl-TKB domain complexed with its binding motif in c-Met Deposited 2008-01-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 6 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain C
997–1009（13 aa）
Fragment：UNP residues 997-1009, pTyr-1003 phosphopeptide
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；298 K；0.15M malic acid, 20% PEG 3350, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 1.35 Å R-free 0.240 |
| 3C1X Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-MET in complex with a Pyrrolotriazine based inhibitor Deposited 2008-01-24 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1049–1360（312 aa）
Fragment：tyrosine kinase domain, UNP residues 1049-1360
|
Mutation：Y1194F, Y1234F, Y1235D, V1272L | CKK N-{[4-({5-[(4-aminopiperidin-1-yl)methyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}oxy)-3-fluorophenyl]carbamoyl}-2-(4-fluorophenyl)acetamide × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.17 Å R-free 0.262 |
| 3CCN X-ray structure of c-Met with triazolopyridazine inhibitor. Deposited 2008-02-26 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1048–1350（303 aa）
Fragment：protein kinase domain,c-Met kinase domain
|
Not recorded | LKG 4-[(6-phenyl[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methyl]phenol × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7.8；298 K；0.1M HEPES pH 7.8, 15% PEG 4K, 6% 2-Propanol, 40mM BME, and 3% Ethanol., VAPOR DIFFUSION, temperature 298K
|
Resolution 1.90 Å R-free 0.275 |
| 3CD8 X-ray Structure of c-Met with triazolopyridazine Inhibitor. Deposited 2008-02-26 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1048–1350（303 aa）
Fragment：protein kinase domain, c-Met kinase domain
|
Not recorded | L5G 7-methoxy-4-[(6-phenyl[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy]quinoline × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7.8；298 K；0.1M HEPES pH 7.8, 15% PEG 4K, 6% 2-Propanol, 40mM BME, and 3% Ethanol, VAPOR DIFFUSION, temperature 298K
|
Resolution 2.00 Å R-free 0.287 |
| 3CE3 Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor C-MET in complex with a Pyrrolopyridinepyridone based inhibitor Deposited 2008-02-28 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1049–1360（312 aa）
Fragment：TYROSINE KINASE DOMAIN, UNP RESIDUES 1049-1360
|
Mutation：Y1194F, Y1234F, Y1235D, V1272L | 1FN 1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.1；12% MEPEG 5000, 0.1M HEPES, 11% 2-PROPANOL., pH 7.1
|
Resolution 2.40 Å R-free 0.275 |
| 3CTH Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-met in complex with a aminopyridine based inhibitor Deposited 2008-04-14 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1049–1360（312 aa）
Fragment：TYROSINE KINASE, UNP RESIDUES 1049-1360
|
Mutation：YES | 319 N-({4-[(2-aminopyridin-4-yl)oxy]-3-fluorophenyl}carbamoyl)-2-(4-fluorophenyl)acetamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.1；12% MEPEG 5000, 0.1M HEPES (PH 7.1) 11% 2-PROPANOL
|
Resolution 2.30 Å R-free 0.273 |
| 3CTJ Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-met in complex with a aminopyridine based inhibitor Deposited 2008-04-14 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1049–1360（312 aa）
Fragment：TYROSINE KINASE, UNP RESIDUES 1049-1360
|
Mutation：YES | 320 2-(4-fluorophenyl)-N-{[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]carbamoyl}acetamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.1；12% MEPEG 5000, 0.1M HEPES (PH 7.1) 11% 2-PROPANOL
|
Resolution 2.50 Å R-free 0.261 |
| 3DKC Structure of MET receptor tyrosine kinase in complex with ATP Deposited 2008-06-24 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1049–1360（312 aa）
|
Mutation：Y1194F, Y1234F, Y1235D | MG MAGNESIUM ION × 1 CL CHLORIDE ION × 1 ATP ADENOSINE-5'-TRIPHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.2；292 K；11% ISOPROPANOL, 2.5% PEG 5K MME, 100 mM BIS-TRIS, pH 6.2, VAPOR DIFFUSION, temperature 292K
|
Resolution 1.52 Å R-free 0.218 |
| 3DKF Structure of MET receptor tyrosine kinase in complex with inhibitor SGX-523 Deposited 2008-06-24 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1049–1360（312 aa）
|
Mutation：Y1194F, Y1234F, Y1235D | CL CHLORIDE ION × 1 SX8 6-{[6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}quinoline × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7.5；292 K；20% ISOPROPANOL, 200 mM AMMONIUM ACETATE, 100 mM TRIS, pH 7.5, VAPOR DIFFUSION, temperature 292K
|
Resolution 1.80 Å R-free 0.233 |
| 3DKG Structure of Mutant(Y1248L) MET receptor tyrosine kinase in complex with inhibitor SGX-523 Deposited 2008-06-24 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1049–1360（312 aa）
|
Mutation：Y1212F, Y1248L, Y1252F, Y1253D | CL CHLORIDE ION × 1 SX8 6-{[6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}quinoline × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 5.8；292 K；11% ISOPROPANOL, 3% PEG 5K MME, 100 mM BIS-TRIS, pH 5.8, VAPOR DIFFUSION, temperature 292K
|
Resolution 1.91 Å R-free 0.238 |
| 3EFJ Structure of c-Met with pyrimidone inhibitor 7 Deposited 2008-09-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
1048–1351（304 aa）
Fragment：c-Met kinase domain, UNP residues 1048-1351
Chain B
1048–1351（304 aa）
Fragment：c-Met kinase domain, UNP residues 1048-1351
|
Mutation：V1272L Mutation：V1272L | MT3 2-benzyl-5-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]-3-fluorophenyl}-3-methylpyrimidin-4(3H)-one × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 5；298 K；12% PEG 6000, 1.0M LiCl2, 0.1M Sodium Citrate, pH 5.0, VAPOR DIFFUSION, temperature 298K
|
Resolution 2.60 Å R-free 0.288 |
| 3EFJ Structure of c-Met with pyrimidone inhibitor 7 Deposited 2008-09-09 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1048–1351（304 aa）
Fragment：c-Met kinase domain, UNP residues 1048-1351
|
Mutation：V1272L | MT3 2-benzyl-5-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]-3-fluorophenyl}-3-methylpyrimidin-4(3H)-one × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 5；298 K；12% PEG 6000, 1.0M LiCl2, 0.1M Sodium Citrate, pH 5.0, VAPOR DIFFUSION, temperature 298K
|
Resolution 2.60 Å R-free 0.288 |
| 3EFJ Structure of c-Met with pyrimidone inhibitor 7 Deposited 2008-09-09 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
1048–1351（304 aa）
Fragment：c-Met kinase domain, UNP residues 1048-1351
|
Mutation：V1272L | MT3 2-benzyl-5-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]-3-fluorophenyl}-3-methylpyrimidin-4(3H)-one × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 5；298 K；12% PEG 6000, 1.0M LiCl2, 0.1M Sodium Citrate, pH 5.0, VAPOR DIFFUSION, temperature 298K
|
Resolution 2.60 Å R-free 0.288 |
| 3EFK Structure of c-Met with pyrimidone inhibitor 50 Deposited 2008-09-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
1048–1351（304 aa）
Fragment：c-Met kinase domain, UNP residues 1048-1351
Chain B
1048–1351（304 aa）
Fragment：c-Met kinase domain, UNP residues 1048-1351
|
Mutation：V1272L Mutation：V1272L | MT4 5-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]-3-fluorophenyl}-2-[(4-fluorophenyl)amino]-3-methylpyrimidin-4(3H)-one × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 5；298 K；12% PEG 6000, 1.0M LiCl2, 0.1M Sodium Citrate, pH 5.0, VAPOR DIFFUSION, temperature 298K
|
Resolution 2.20 Å R-free 0.292 |
| 3EFK Structure of c-Met with pyrimidone inhibitor 50 Deposited 2008-09-09 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1048–1351（304 aa）
Fragment：c-Met kinase domain, UNP residues 1048-1351
|
Mutation：V1272L | MT4 5-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]-3-fluorophenyl}-2-[(4-fluorophenyl)amino]-3-methylpyrimidin-4(3H)-one × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 5；298 K；12% PEG 6000, 1.0M LiCl2, 0.1M Sodium Citrate, pH 5.0, VAPOR DIFFUSION, temperature 298K
|
Resolution 2.20 Å R-free 0.292 |
| 3EFK Structure of c-Met with pyrimidone inhibitor 50 Deposited 2008-09-09 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
1048–1351（304 aa）
Fragment：c-Met kinase domain, UNP residues 1048-1351
|
Mutation：V1272L | MT4 5-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]-3-fluorophenyl}-2-[(4-fluorophenyl)amino]-3-methylpyrimidin-4(3H)-one × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 5；298 K；12% PEG 6000, 1.0M LiCl2, 0.1M Sodium Citrate, pH 5.0, VAPOR DIFFUSION, temperature 298K
|
Resolution 2.20 Å R-free 0.292 |
| 3F66 Human c-Met Kinase in complex with quinoxaline inhibitor Deposited 2008-11-05 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1052–1349（298 aa）
Fragment：UNP residues 1052-1349
|
Not recorded | IHX 3-[3-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)quinoxalin-5-yl]phenol × 1 GBL GAMMA-BUTYROLACTONE × 3 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.40 Å R-free 0.225 |
| 3F66 Human c-Met Kinase in complex with quinoxaline inhibitor Deposited 2008-11-05 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
1052–1349（298 aa）
Fragment：UNP residues 1052-1349
|
Not recorded | IHX 3-[3-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)quinoxalin-5-yl]phenol × 1 GBL GAMMA-BUTYROLACTONE × 2 NA SODIUM ION × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.40 Å R-free 0.225 |
| 3F82 Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor C-MET in complex with N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide Deposited 2008-11-11 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1049–1360（312 aa）
Fragment：RESIDUES 1049-1360
|
Mutation：YES | 353 N-{4-[(2-amino-3-chloropyridin-4-yl)oxy]-3-fluorophenyl}-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.1；12% MEPEG 5000, 0.1M HEPES (PH 7.1) 11% 2-PROPANOL
|
Resolution 2.50 Å R-free 0.253 |
| 3I5N Crystal structure of c-Met with triazolopyridazine inhibitor 13 Deposited 2009-07-06 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1048–1350（303 aa）
Fragment：kinase domain (UNP residues 1048 to 1350)
|
Mutation：V1272L | B2D 7-methoxy-N-[(6-phenyl[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methyl]-1,5-naphthyridin-4-amine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7.8；298 K；15% PEG 4000, 0.1 M HEPES, 40 mM beta-mercaptoethanol, 6% isopropanol, 3% ethanol
, pH 7.8, VAPOR DIFFUSION, temperature 298K
|
Resolution 2.00 Å R-free 0.267 |
| 3L8V Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor C-MET in complex with a biarylamine based inhibitor Deposited 2010-01-04 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1049–1360（312 aa）
Fragment：TYROSINE KINASE DOMAIN, UNP RESIDUES 1049-1360
|
Not recorded | L8V 2-({4-[(2-aminopyridin-4-yl)oxy]-3-fluorophenyl}amino)-N-(2,4-difluorophenyl)pyridine-3-carboxamide × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.40 Å R-free 0.237 |
| 3LQ8 Structure of the kinase domain of c-Met bound to XL880 (GSK1363089) Deposited 2010-02-08 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1051–1348（298 aa）
Fragment：tyrosine kinase domain
|
Not recorded | 88Z N-(3-fluoro-4-{[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；12% PEG 4000, 15% isopropanol, 25 mM MOPS, pH 6.5, 150 mM NaCl, 2 mM DTT, VAPOR DIFFUSION, SITTING DROP, temperature 291K
|
Resolution 2.02 Å R-free 0.252 |
| 3Q6U Structure of the apo MET receptor kinase in the dually-phosphorylated, activated state Deposited 2011-01-03 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1048–1348（301 aa）
Fragment：residues 1048-1348, Kinase Domain
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；293 K；15.6 mg/ml protein mixed in 1:1 ratio with reservoir containing 150 mM malic acid, 20% PEG3350., pH 7.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 1.60 Å R-free 0.214 |
| 3Q6W Structure of dually-phosphorylated MET receptor kinase in complex with an MK-2461 analog with specificity for the activated receptor Deposited 2011-01-03 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1048–1348（301 aa）
Fragment：residues 1048-1348, Kinase Domain
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | Q6W 3-{5-oxo-3-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl}-N-(pyridin-2-ylmethyl)propanamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；293 K；15.6 mg/ml protein mixed 1:1 with a reservoir solution of 150 mM malic acid, 20% PEG3350. 2-fold molar excess of ligand was added for co-crystallization., pH 7.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 1.75 Å R-free 0.227 |
| 3QTI c-Met Kinase in Complex with NVP-BVU972 Deposited 2011-02-22 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1050–1360（311 aa）
Fragment：kinase domain, residues 1050-1360
|
Not recorded | 3QT 6-{[6-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-b]pyridazin-3-yl]methyl}quinoline × 1 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；Equal Volumes Protein and a Reservoir Solution composed of 100 mM Hepes pH 7.5, 16% PEG 4000, 8% isopropanol, and 3 mM TCEP were mixed with microseeds., VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.00 Å R-free 0.213 |
| 3QTI c-Met Kinase in Complex with NVP-BVU972 Deposited 2011-02-22 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
1050–1360（311 aa）
Fragment：kinase domain, residues 1050-1360
|
Not recorded | 3QT 6-{[6-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-b]pyridazin-3-yl]methyl}quinoline × 1 CL CHLORIDE ION × 1 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；Equal Volumes Protein and a Reservoir Solution composed of 100 mM Hepes pH 7.5, 16% PEG 4000, 8% isopropanol, and 3 mM TCEP were mixed with microseeds., VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.00 Å R-free 0.213 |
| 3R7O Structure of dually phosphorylated c-MET receptor kinase in complex with an MK-2461 analog Deposited 2011-03-22 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1048–1348（301 aa）
Fragment：kinase domain (UNP residues 1048-1348)
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | M61 N-[(2R)-1,4-dioxan-2-ylmethyl]-N-methyl-N'-{5-oxo-3-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl}sulfuric diamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；15.6 mg/ml protein mixed in 1:1 ratio with reservoir containing 150 mM malic acid, 20% PEG3350, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.30 Å R-free 0.240 |
| 3RHK Crystal structure of the catalytic domain of c-Met kinase in complex with ARQ 197 Deposited 2011-04-11 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1038–1346（309 aa）
Fragment：UNP residues 1038-1346
|
Not recorded | M97 1-[(3R,4R)-4-(1H-indol-3-yl)-2,5-dioxopyrrolidin-3-yl]pyrrolo[3,2,1-ij]quinolinium × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；13% ethanol, 12% ethylene glycol, 100mM imidazole, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 1.94 Å R-free 0.254 |
| 3RHK Crystal structure of the catalytic domain of c-Met kinase in complex with ARQ 197 Deposited 2011-04-11 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
1038–1346（309 aa）
Fragment：UNP residues 1038-1346
|
Not recorded | M97 1-[(3R,4R)-4-(1H-indol-3-yl)-2,5-dioxopyrrolidin-3-yl]pyrrolo[3,2,1-ij]quinolinium × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；13% ethanol, 12% ethylene glycol, 100mM imidazole, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 1.94 Å R-free 0.254 |
| 3U6H Crystal structure of c-Met in complex with pyrazolone inhibitor 26 Deposited 2011-10-12 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1048–1351（304 aa）
Fragment：unp residues 1048-1351
|
Not recorded | 03X N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]-3-fluorophenyl}-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 5；293 K；12% PEG 6000, 1.0 M lithium chloride, 0.1 M sodium citrate, pH 5.0, VAPOR DIFFUSION, temperature 293K
|
Resolution 2.00 Å R-free 0.274 |
| 3U6H Crystal structure of c-Met in complex with pyrazolone inhibitor 26 Deposited 2011-10-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
1048–1351（304 aa）
Fragment：unp residues 1048-1351
|
Not recorded | 03X N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]-3-fluorophenyl}-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 5；293 K；12% PEG 6000, 1.0 M lithium chloride, 0.1 M sodium citrate, pH 5.0, VAPOR DIFFUSION, temperature 293K
|
Resolution 2.00 Å R-free 0.274 |
| 3U6I Crystal structure of c-Met in complex with pyrazolone inhibitor 58a Deposited 2011-10-12 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1048–1351（304 aa）
Fragment：unp residues 1048-1315
|
Not recorded | 044 N-{3-fluoro-4-[(7-methoxyquinolin-4-yl)oxy]phenyl}-1-[(2R)-2-hydroxypropyl]-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 5；293 K；12% PEG 6000, 1.0 M lithium chloride, 0.1 M sodium citrate, pH 5.0, VAPOR DIFFUSION, temperature 293K
|
Resolution 2.10 Å R-free 0.257 |
| 3U6I Crystal structure of c-Met in complex with pyrazolone inhibitor 58a Deposited 2011-10-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
1048–1351（304 aa）
Fragment：unp residues 1048-1315
|
Not recorded | 044 N-{3-fluoro-4-[(7-methoxyquinolin-4-yl)oxy]phenyl}-1-[(2R)-2-hydroxypropyl]-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 5；293 K；12% PEG 6000, 1.0 M lithium chloride, 0.1 M sodium citrate, pH 5.0, VAPOR DIFFUSION, temperature 293K
|
Resolution 2.10 Å R-free 0.257 |
| 3VW8 Crystal structure of human c-Met kinase domain with its inhibitor Deposited 2012-08-08 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1024–1352（329 aa）
Fragment：UNP RESIDUES 1024-1352
|
Not recorded | DF6 N-({4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}carbamothioyl)-2-phenylacetamide × 1 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；0.1M HEPES, 25% PEG2000, 8% isopropanol, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 2.10 Å R-free 0.259 |
| 3ZBX X-ray Structure of c-Met kinase in complex with inhibitor 6-((6-(4- fluorophenyl)-(1,2,4)triazolo(4,3-b)(1,2,4)triazin-3-yl)methyl) quinoline. Deposited 2012-11-13 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1051–1348（298 aa）
Fragment：TYROSINE KINASE DOMAIN, UNP RESIDUES 1051-1348
|
Not recorded | 6XE 6-[[6-(4-fluorophenyl)-[1,2,4]triazolo[4,3-b][1,2,4]triazin-3-yl]methyl]quinoline × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.2；286 K；C-MET COCRYSTALS WERE OBTAINED AT 13 DEGREES C BY THE HANGING DROP VAPOR DIFFUSION METHOD BY MIXING 1.2 MICROLITERS OF PROTEIN SOLUTION (CONTAINING 7-13 MG/ML C-MET KD (RESIDUES 1051-1348) WITH A 5 FOLD MOLAR EXCESS OF C-MET INHIBITOR COMPOUND) WITH 1.2 MICROLITERS OF SOLUTION CONTAINING (0.05M CITRATE-PHOSPHATE PH 4.2, 200M NACL, AND 17.4% POLYETHYLENE GLYCOL MW=3350)
|
Resolution 2.20 Å R-free 0.237 |
| 3ZC5 X-ray Structure of c-Met kinase in complex with inhibitor (S)-6-(1-(6- (1-methyl-1H-pyrazol-4-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)ethyl) quinoline. Deposited 2012-11-15 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1051–1348（298 aa）
Fragment：TYROSINE KINASE DOMAIN, UNP RESIDUES 1051-1348
|
Not recorded | W9Z 6-{(1S)-1-[6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]ethyl}quinoline × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.6；286 K；C-MET COCRYSTALS WERE OBTAINED AT 13 DEGREES C BY THE HANGING DROP VAPOR DIFFUSION METHOD BY MIXING 1.2 MICROL OF PROTEIN SOLUTION (CONTAINING 7-13 MG/ML C-MET KD (RESIDUES 1051-1348) WITH A 5 FOLD MOLAR EXCESS OF SELECTED C-MET INHIBITOR) WITH 1.2 MICROL OF SOLUTION CONTAINING (0.05 M CITRATE-PHOSPHATE PH 4.6, 0-0.275 M NACL, AND 17-21% POLYETHYLENE GLYCOL MW=3350).
|
Resolution 2.20 Å R-free 0.256 |
| 3ZCL X-ray Structure of c-Met kinase in complex with inhibitor (S)-3-(1-(1H-pyrrolo(2,3-b)pyridin-3-yl)ethyl)-N-isopropyl-(1,2,4)triazolo(4,3- b)pyridazin-6-amine Deposited 2012-11-20 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1051–1348（298 aa）
Fragment：TYROSINE KINASE DOMAIN, UNP RESIDUES 1051-1348
|
Not recorded | 5TF (S)-3-(1-(1H-pyrrolo(2,3-b)pyridin-3-yl)ethyl)-N-isopropyl-(1,2,4)triazolo(4,3-b)pyridazin-6-amine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.6；286 K；C-MET COCRYSTALS WERE OBTAINED AT 13 DEGREES C BY THE HANGING DROP VAPOR DIFFUSION METHOD BY MIXING 1.2 MICROL OF PROTEIN SOLUTION (CONTAINING 7-13 MG/ML C-MET KD (RESIDUES 1051-1348) WITH A 5 FOLD MOLAR EXCESS OF SELECTED C-MET INHIBITOR) WITH 1.2 MICROL OF SOLUTION CONTAINING (0.05 M CITRATE-PHOSPHATE PH 4.6, 0-0.275 M NACL, AND 17-21% POLYETHYLENE GLYCOL MW=3350).
|
Resolution 1.40 Å R-free 0.211 |
| 3ZXZ X-ray Structure of PF-04217903 bound to the kinase domain of c-Met Deposited 2011-08-16 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1051–1348（298 aa）
Fragment：TYROSINE KINASE DOMAIN, RESIDUES 1051-1348
|
Not recorded | KRW 2-{4-[1-(QUINOLIN-6-YLMETHYL)-1H-[1,2,3]TRIAZOLO[4,5-B]PYRAZIN-6-YL]-1H-PYRAZOL-1-YL}ETHANOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.6；286 K；CRYSTALS WERE OBTAINED AT 13 DEGREES C BY THE HANGING DROP VAPOR DIFFUSION METHOD USING 1.2 MICROLITERS OF PROTEIN SOLUTION (CONTAINING 7-13 MG/ML C-MET KD PLUS A 5 FOLD MOLAR EXCESS OF PF-04217903) AND 1.2 MICROLITERS OF MOTHER LIQUOR SOLUTION (0.05 M CITRATE-PHOSHPHATE 4.6, 0-0.275 M NACL, AND 21% W/V PEG 3350).
|
Resolution 1.80 Å R-free 0.221 |
| 3ZZE Crystal structure of C-MET kinase domain in complex with N'-((3Z)-4- chloro-7-methyl-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2-(4- hydroxyphenyl)propanohydrazide Deposited 2011-08-31 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1051–1348（298 aa）
Fragment：TYROSINE KINASE DOMAIN, UNP RESIDUES 1051-1348
|
Not recorded | 6XP (2S)-N'-[(3R)-4-chloro-7-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-2-(4-hydroxyphenyl)propanehydrazide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.6；286 K；CRYSTALS WERE OBTAINED AT 13 DEGREES C BY THE HANGING DROP VAPOR DIFFUSION METHOD USING 1.2 MICROLITERS OF PROTEIN SOLUTION (CONTAINING 7-13 MG/ML C-MET KD PLUS A 5 FOLD MOLAR EXCESS OF THE C-MET INHIBITOR COMPOUND) AND 1.2 MICROLITERS OF MOTHER LIQUOR SOLUTION (0.05 M CITRATE-PHOSHPHATE 4.6, 0-0.275 M NACL, AND 21% W/V PEG 3350).
|
Resolution 1.87 Å R-free 0.226 |
| 4AOI Crystal structure of C-MET kinase domain in complex with 4-(3-((1H- pyrrolo(2,3-b)pyridin-3-yl)methyl)-(1,2,4)triazolo(4,3-b)(1,2,4) triazin-6-yl)benzonitrile Deposited 2012-03-27 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1051–1348（298 aa）
Fragment：TYROSINE KINASE DOMAIN, RESIDUES 1051-1348
|
Not recorded | 4K0 4-[3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-[1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl]benzenecarbonitrile × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；286 K；CRYSTALS WERE OBTAINED AT 13 DEGREES CELCIUS FROM HANGING DROPS CONTAINING 1.2 MICROLITERS OF PROTEIN: COMPOUND SOLUTION (1:5 MOLAR RATIO) AND 1.2 MICROLITERS OF PRECIPITATING SOLUTION (0.05 M CITRATE-PHOSPHATE, PH 4.6, 0-25 MM NACL, 21 % (W/V) PEG-3350). TO OBTAIN LARGER CRYSTALS, STREAK SEEDING WAS EMPLOYED USING THE CRYSTALS JUST MENTIONED AS DONORS, UNDER THE SAME CONDITIONS EXCEPT 275 MM NACL WAS USED AND THE DROPS WERE EQUILIBRATED OVERNIGHT BEFORE SEEDING WAS PERFORMED.
|
Resolution 1.90 Å R-free 0.214 |
| 4AP7 Crystal structure of C-MET kinase domain in complex with 4-((6-(4- fluorophenyl)-(1,2,4)triazolo(4,3-b)(1,2,4)triazin-3-yl)methyl)phenol Deposited 2012-03-30 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1051–1348（298 aa）
Fragment：TYROSINE KINASE DOMAIN, UNP RESIDUES 1051-1348
|
Not recorded | F47 4-[[6-(4-fluorophenyl)-[1,2,4]triazolo[4,3-b][1,2,4]triazin-3-yl]methyl]phenol × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.6；286 K；CRYSTALS WERE OBTAINED AT 13 DEGRESS C IN 1-5 DAYS FROM HANGING DROPS CONTAINING 1.2 MICROLITERS OF PROTEIN: COMPOUND SOLUTION (1:5 MOLAR RATIO) AND 1.2 MICROLITERS OF PRECIPITATING SOLUTION (0.05 M CITRATE-PHOSPHATE, PH 4.6, 0-25 MM NACL, 21 % (W/V) PEG-3350). TO OBTAIN LARGER CRYSTALS, STREAK SEEDING WAS EMPLOYED USING THE CRYSTALS JUST MENTIONED AS DONORS, UNDER THE SAME CONDITIONS EXCEPT 275 MM NACL WAS USED AND THE DROPS WERE EQUILIBRATED OVERNIGHT BEFORE SEEDING WAS PERFORMED
|
Resolution 1.80 Å R-free 0.214 |
| 4DEG Crystal structure of c-Met in complex with triazolopyridazine inhibitor 2 Deposited 2012-01-20 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1048–1351（304 aa）
|
Not recorded | 0JJ 7-methoxy-N-{[6-(3-methyl-1,2-thiazol-5-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}-1,5-naphthyridin-4-amine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.8；293 K；15% PEG 4000, 0.1 M HEPES, 6% isopropanol, 3% ethanol, 40 mM beta-mercaptoethanol, pH 7.8, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.00 Å R-free 0.254 |
| 4DEH Crystal structure of c-Met in complex with triazolopyridinone inhibitor 3 Deposited 2012-01-20 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1048–1351（304 aa）
|
Not recorded | 0JK 5-phenyl-3-(quinolin-6-ylmethyl)-3,5,6,7-tetrahydro-4H-[1,2,3]triazolo[4,5-c]pyridin-4-one × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.8；293 K；15% PEG 4000, 0.1 M HEPES, 6% isopropanol, 3% ethanol, 40 mM beta-mercaptoethanol, pH 7.8, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.00 Å R-free 0.259 |
| 4DEI Crystal structure of c-Met in complex with triazolopyridinone inhibitor 24 Deposited 2012-01-20 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1048–1351（304 aa）
|
Not recorded | 0JL 3-{(1S)-1-[3-(2-methoxyethoxy)quinolin-6-yl]ethyl}-5-(3-methyl-1,2-thiazol-5-yl)-3,5-dihydro-4H-[1,2,3]triazolo[4,5-c]pyridin-4-one × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.8；293 K；15% PEG 4000, 0.1 M HEPES, 6% isopropanol, 3% ethanol, 40 mM beta-mercaptoethanol, pH 7.8, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.05 Å R-free 0.289 |
| 4EEV Crystal structure of c-Met in complex with LY2801653 Deposited 2012-03-28 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1038–1346（309 aa）
Fragment：kinase domain (unp residues 1038-1346)
|
Not recorded | L1X N-(3-fluoro-4-{[1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yl]oxy}phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；298 K；16% PEG 10.000, 0.1 M HEPES, and 5% ethylene glycol, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 298.0K
|
Resolution 1.80 Å R-free 0.215 |
| 4GG5 Crystal structure of CMET in complex with novel inhibitor Deposited 2012-08-05 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1038–1346（309 aa）
|
Not recorded | 0J3 3-(4-methylpiperazin-1-yl)-N-(3-nitrobenzyl)-7-(trifluoromethyl)quinolin-5-amine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M HEPES, 8% isopropanol, 3mM TECP, 16% PEG4000, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.42 Å R-free 0.268 |
| 4GG7 Crystal structure of cMET in complex with novel inhibitor Deposited 2012-08-06 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1038–1346（309 aa）
|
Not recorded | 0J8 N-(3-nitrobenzyl)-6-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]-2-(trifluoromethyl)pyrido[2,3-d]pyrimidin-4-amine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M Tris-HCl, 15% glycerol, 12% MPD, 5% isopropanol, 14% PEG5000, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.27 Å R-free 0.262 |
| 4IWD Structure of dually phosphorylated c-MET receptor kinase in complex with an MK-8033 analog Deposited 2013-01-23 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1048–1348（301 aa）
Fragment：UNP residues 1048-1348
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | 1JC 1-{5-oxo-3-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl}-N-(pyridin-2-ylmethyl)methanesulfonamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；15.6 mg/ml protein mixed in 1:1 ratio with reservoir containing 150 mM malic acid, 20% PEG3350, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.99 Å R-free 0.257 |
| 4K3J Crystal structure of Onartuzumab Fab in complex with MET and HGF-beta Deposited 2013-04-10 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain B
39–564（526 aa）
Fragment：Sema and PSI domain, UNP residues 39-564
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.2；298 K；0.1 M sodium cacodylate pH 6.2, 20% (w/v) PEG 4000, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.80 Å R-free 0.253 |
| 4KNB C-Met in complex with OSI ligand Deposited 2013-05-09 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1060–1346（287 aa）
Fragment：protein kinase domain (UNP residues 1060-1346)
|
Not recorded | 1RU 7-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-3-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]furo[3,2-c]pyridin-6-amine × 1 GBL GAMMA-BUTYROLACTONE × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
LIQUID DIFFUSION；LIQUID DIFFUSION
|
Resolution 2.40 Å R-free 0.288 |
| 4KNB C-Met in complex with OSI ligand Deposited 2013-05-09 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
1060–1346（287 aa）
Fragment：protein kinase domain (UNP residues 1060-1346)
|
Not recorded | 1RU 7-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-3-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]furo[3,2-c]pyridin-6-amine × 1 GBL GAMMA-BUTYROLACTONE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
LIQUID DIFFUSION；LIQUID DIFFUSION
|
Resolution 2.40 Å R-free 0.288 |
| 4KNB C-Met in complex with OSI ligand Deposited 2013-05-09 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain C
1060–1346（287 aa）
Fragment：protein kinase domain (UNP residues 1060-1346)
|
Not recorded | 1RU 7-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-3-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]furo[3,2-c]pyridin-6-amine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
LIQUID DIFFUSION；LIQUID DIFFUSION
|
Resolution 2.40 Å R-free 0.288 |
| 4KNB C-Met in complex with OSI ligand Deposited 2013-05-09 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 4 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain D
1060–1346（287 aa）
Fragment：protein kinase domain (UNP residues 1060-1346)
|
Not recorded | 1RU 7-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-3-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]furo[3,2-c]pyridin-6-amine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
LIQUID DIFFUSION；LIQUID DIFFUSION
|
Resolution 2.40 Å R-free 0.288 |
| 4MXC Crystal structure of CMET in complex with novel inhibitor Deposited 2013-09-26 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1038–1346（309 aa）
Fragment：Protein Kinase domain, UNP resodies 1038-1346
|
Not recorded | DWF N-(3-fluoro-4-{[2-({3-[(methylsulfonyl)methyl]phenyl}amino)pyrimidin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；19-20%(w/v)PEG 3350, 200mM MgSO4, 100mM Tris-HCl, pH 7.5, vapor diffusion, hanging drop, temperature 293K
|
Resolution 1.63 Å R-free 0.207 |
| 4O3T Zymogen HGF-beta/MET with Zymogen Activator Peptide ZAP.14 Deposited 2013-12-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 3 PDB declaration: trimeric |
Chain B
25–567（543 aa）
Fragment：Sema-PSI (UNP Residues 496-728)
|
Mutation：L303K/V304R/P305K/R306K/G307R | 1PE PENTAETHYLENE GLYCOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；PEG6000, 800 mM NaCl, 400 mM trimethylammonium oxide, pH 8.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.99 Å R-free 0.276 |
| 4O3U Zymogen HGF-beta/MET with Zymogen Activator Peptide ZAP2.3 Deposited 2013-12-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain B
25–567（543 aa）
Fragment：Sema-PSI (UNP Residues 496-728)
|
Mutation：L303K/V304R/P305K/R306K/G307R | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.2；293 K；8% PEG8000, pH 7.2, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 3.04 Å R-free 0.251 |
| 4R1V Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors Deposited 2014-08-07 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1055–1345（291 aa）
Fragment：KINASE DOMAIN, UNP residues 1055-1345
|
Not recorded | 3E8 3-[1-(3-{5-[(1-methylpiperidin-4-yl)methoxy]pyrimidin-2-yl}benzyl)-6-oxo-1,6-dihydropyridazin-3-yl]benzonitrile × 1 GBL GAMMA-BUTYROLACTONE × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；298 K；PEG 8000, pH 6.5, VAPOR DIFFUSION, temperature 298K
|
Resolution 1.20 Å R-free 0.176 |
| 4R1Y Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitor Deposited 2014-08-08 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1055–1346（292 aa）
Fragment：Kinase domain, UNP residues 1055-1346
|
Not recorded | 3EH 3-(diethylamino)propyl (3-{[5-(3,4-dimethoxyphenyl)-2-oxo-2H-1,3,4-thiadiazin-3(6H)-yl]methyl}phenyl)carbamate × 1 7PE 2-(2-(2-(2-(2-(2-ETHOXYETHOXY)ETHOXY)ETHOXY)ETHOXY)ETHOXY)ETHANOL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；298 K；PEG8000, pH 6.5, VAPOR DIFFUSION, temperature 298K
|
Resolution 2.00 Å R-free 0.238 |
| 4XMO Crystal structure of c-Met in complex with (R)-5-(8-fluoro-3-(1-fluoro-1-(3-methoxyquinolin-6-yl)ethyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yl)-3-methylisoxazole Deposited 2015-01-14 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1048–1350（303 aa）
Fragment：kinase domain (UNP residues 1048-1350)
|
Not recorded | 46G 6-{(1R)-1-fluoro-1-[8-fluoro-6-(3-methyl-1,2-oxazol-5-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl}-3-methoxyquinoline × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.8；298 K；12% PEG 4000, 100 mM HEPES, pH 7.8, 6% isopropanol, 3% ethanol, 40 mM beta-mercaptoethanol
|
Resolution 1.75 Å R-free 0.238 |
| 4XYF Crystal structure of c-Met in complex with (S)-5-(8-fluoro-3-(1-(3-(2-methoxyethoxy)quinolin-6-yl)ethyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yl)-3-methylisoxazole Deposited 2015-02-02 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1048–1351（304 aa）
Fragment：kinase domain (UNP residues 1048-1351)
|
Not recorded | 44X 6-{(1S)-1-[8-fluoro-6-(3-methyl-1,2-oxazol-5-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl}-3-(2-methoxyethoxy)quinoline × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.8；298 K；13% PEG 4000, 100 mM HEPES, 6% (v/v) isopropanol, 3% (v/v) ethanol, 40 mM beta-mercaptoethanol
|
Resolution 1.85 Å R-free 0.236 |
| 5DG5 CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH ALTIRATINIB ANALOG DP-4157 Deposited 2015-08-27 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
1056–1364（309 aa）
Chain B
1056–1364（309 aa）
|
Not recorded | 5B4 N-(2,5-difluoro-4-{[2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxam ide × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；290 K；Protein at 9.5mg/ml in 20 mM Tris pH 8.5, 100mM NaCl, 14mM 2-mercaptoethanol with 5-molar excess of compound; crystallization condition: 1.0M diammonium hydrogen phosphate, 0.2M sodium chloride, 0.1M citrate pH 5.0 and 7.5% glycerol
|
Resolution 2.60 Å R-free 0.245 |
| 5EOB Crystal structure of CMET in complex with novel inhibitor Deposited 2015-11-10 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1038–1346（309 aa）
Fragment：UNP residues 1038-1346
|
Not recorded | 5QQ 6-[bis(fluoranyl)-[6-(4-fluorophenyl)-[1,2,4]triazolo[4,3-b][1,2,4]triazin-3-yl]methyl]quinoline × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；19-20%(w/v)PEG 3350, 200mM MgSO4, 100mM Tris-HCl
|
Resolution 1.75 Å R-free 0.197 |
| 5EYC Crystal structure of c-Met in complex with naphthyridinone inhibitor 5 Deposited 2015-11-24 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1048–1351（304 aa）
Fragment：residues 1048-1351
|
Not recorded | 5SZ 6-[(1~{R})-1-[8-fluoranyl-6-(3-methyl-1,2-oxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl]-1,6-naphthyridin-5-one × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.8；293 K；12% PEG 4000, 3% (v/v) ethanol, 6% (v/v) isopropanol, 40 mM beta-mercaptoethanol, 100 mM HEPES (pH 7.8)
|
Resolution 1.80 Å R-free 0.247 |
| 5EYD Crystal structure of c-Met in complex with AMG 337 Deposited 2015-11-24 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1048–1351（304 aa）
Fragment：residues 1048-1351
|
Not recorded | 5T1 6-[(1~{R})-1-[8-fluoranyl-6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl]-3-(2-methoxyethoxy)-1,6-naphthyridin-5-one × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.8；293 K；12% PEG 4000, 3% (v/v) ethanol, 6% (v/v) isopropanol, 40 mM beta-mercaptoethanol, 100 mM HEPES (pH 7.8)
|
Resolution 1.85 Å R-free 0.249 |
| 5HLW Crystal structure of c-Met mutant Y1230H in complex with compound 14 Deposited 2016-01-15 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1057–1355（299 aa）
|
Mutation：Y1230H | CL CHLORIDE ION × 1 62E 1-[2-(1-ethylpiperidin-4-yl)ethyl]-3-(6-{[6-(thiophen-2-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}-1,3-benzothiazol-2-yl)urea × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；293 K；Tris 100mM-MPD20%-pH8
|
Resolution 1.97 Å |
| 5HNI CRYSTAL STRUCTURE OF CMET WT with compound 3 Deposited 2016-01-18 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain X
1067–1378（312 aa）
Fragment：UNP residues 1067-1378
|
Not recorded | 63B methyl (6-{[6-(4-fluorophenyl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}-1H-benzimidazol-2-yl)carbamate × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；277 K；Hepes 100mM, isopropanol 11%, PEG5000 MME 6%
|
Resolution 1.71 Å R-free 0.245 |
| 5HNI CRYSTAL STRUCTURE OF CMET WT with compound 3 Deposited 2016-01-18 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain Y
1067–1378（312 aa）
Fragment：UNP residues 1067-1378
|
Not recorded | 63B methyl (6-{[6-(4-fluorophenyl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}-1H-benzimidazol-2-yl)carbamate × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；277 K；Hepes 100mM, isopropanol 11%, PEG5000 MME 6%
|
Resolution 1.71 Å R-free 0.245 |
| 5HO6 CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH CMPD. Deposited 2016-01-19 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1049–1360（312 aa）
|
Mutation：Y1230H, Y1194F, Y1234F, Y1235D | 63K 1-(6-{[6-(4-fluorophenyl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}-1,3-benzothiazol-2-yl)-3-[2-(morpholin-4-yl)ethyl]urea × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；Tris 100mM - MPD 20% - pH8.5
|
Resolution 1.97 Å |
| 5HOA Crystal structure of c-Met L1195V in complex with SAR125844 Deposited 2016-01-19 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1049–1360（312 aa）
|
Not recorded | 63K 1-(6-{[6-(4-fluorophenyl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}-1,3-benzothiazol-2-yl)-3-[2-(morpholin-4-yl)ethyl]urea × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；Tris 100 mM, MPD 24%, pH8.5
|
Resolution 2.14 Å |
| 5HOR Crystal structure of c-Met-M1250T in complex with SAR125844. Deposited 2016-01-19 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1049–1360（312 aa）
|
Mutation：M1250T,Y1194F,Y1234F,Y1235D | 63K 1-(6-{[6-(4-fluorophenyl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}-1,3-benzothiazol-2-yl)-3-[2-(morpholin-4-yl)ethyl]urea × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；Tris 100mM, MPD 20%, pH8.5
|
Resolution 2.20 Å |
| 5HTI Crystal structure of c-Met kinase domain in complex with LXM108 Deposited 2016-01-26 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1038–1346（309 aa）
|
Not recorded | 66L N-[3-fluoro-4-({7-[2-(morpholin-4-yl)ethoxy]-1,6-naphthyridin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.1；293 K；10-11% PEG5000MME, 11% isopropanol, 0.1M HEPES pH 7.1
|
Resolution 1.66 Å R-free 0.206 |
| 5LSP 107_A07 Fab in complex with fragment of the Met receptor Deposited 2016-09-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain A
519–743（225 aa）
Chain P
519–743（225 aa）
Chain X
25–35（11 aa）
Chain Y
25–35（11 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；293 K；10% PEG 20,000, 20% PEG 550-MME, 0.1M Trizma/Bicine pH 8.5, 0.03M magnesium chloride, 0.03M calcium chloride
|
Resolution 2.60 Å R-free 0.257 |
| 5T3Q Crystal structure of the c-Met kinase domain in complex with a pyrazolone inhibitor Deposited 2016-08-26 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
1066–1368（303 aa）
Fragment：kinase domain
|
Not recorded | 75H N-{3-fluoro-4-[(7-methoxyquinolin-4-yl)oxy]phenyl}-1-(2-hydroxy-2-methylpropyl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5；298 K；12% PEG 6000, 1.0 M lithium chloride, 0.1 M sodium citrate (pH 5.0)
|
Resolution 2.00 Å R-free 0.248 |
| 5UAB MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF Antibody Deposited 2016-12-19 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1041–1378（338 aa）
Fragment：UNP residues 1041-1378
|
Not recorded | 84M N-{6-[([1,2,4]triazolo[4,3-a]pyridin-3-yl)sulfanyl]imidazo[1,2-b]pyridazin-2-yl}cyclopropanecarboxamide × 1 GOL GLYCEROL × 1 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.8；293 K；16.% PEG MME 5000, 15.% Isopropanol, 0.1M HEPES pH 7.8
|
Resolution 1.90 Å R-free 0.229 |
| 5UAD MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF Antibody Deposited 2016-12-19 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1041–1378（338 aa）
Fragment：UNP residues 1041-1378
|
Not recorded | 84P N-(6-{[6-(1-methyl-1H-pyrazol-4-yl)-1H-benzotriazol-1-yl]methyl}imidazo[1,2-b]pyridazin-2-yl)cyclopropanecarboxamide × 1 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.2；273 K；19.% PEG 3350, 12.% Isopropanol, 0.1M HEPES pH 7.2
|
Resolution 2.25 Å R-free 0.252 |
| 5YA5 CRYSTAL STRUCTURE OF c-MET IN COMPLEX WITH NOVEL INHIBITOR Deposited 2017-08-30 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1038–1346（309 aa）
Fragment：UNP residues 1038-1346
|
Not recorded | 6TD 2-[3-(4-methoxybenzyl)[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-yl]-1H-indole × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M Tris pH7.5, 15% glycerol, 12% MPD, 5% isopropanol, 15% PEG5Kmme
|
Resolution 1.89 Å R-free 0.235 |
| 6GCU MET receptor in complex with InlB internalin domain and DARPin A3A Deposited 2018-04-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain A
25–741（717 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293.15 K；0.1 M HEPES sodium salt pH 7.5, 12% w/v PEG4000, protein complex concentration 5 mg/mL, equimolar ratio of macromolecules, drop size 0.2 uL, protein:reservoir ratio 1:1
|
Resolution 6.00 Å R-free 0.271 |
| 6GCU MET receptor in complex with InlB internalin domain and DARPin A3A Deposited 2018-04-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain D
25–741（717 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293.15 K；0.1 M HEPES sodium salt pH 7.5, 12% w/v PEG4000, protein complex concentration 5 mg/mL, equimolar ratio of macromolecules, drop size 0.2 uL, protein:reservoir ratio 1:1
|
Resolution 6.00 Å R-free 0.271 |
| 6I04 Crystal structure of Sema domain of the Met receptor in complex with FAB Deposited 2018-10-25 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain A
25–564（540 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；18% w/v PEG 3350, 0.1 M ammonium citrate
|
Resolution 3.10 Å R-free 0.261 |
| 6I04 Crystal structure of Sema domain of the Met receptor in complex with FAB Deposited 2018-10-25 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain B
25–564（540 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；18% w/v PEG 3350, 0.1 M ammonium citrate
|
Resolution 3.10 Å R-free 0.261 |
| 6SD9 Crystal structure of wild-type cMET bound by foretinib Deposited 2019-07-26 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1038–1346（309 aa）
|
Not recorded | CL CHLORIDE ION × 1 88Z N-(3-fluoro-4-{[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；15 % 2-propanol, 17 % PEG4K, 0.1 M NaHEPES pH 8
|
Resolution 2.35 Å R-free 0.270 |
| 6SDC Crystal structure of D1228V cMET bound by foretinib Deposited 2019-07-26 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1038–1346（309 aa）
|
Not recorded | 88Z N-(3-fluoro-4-{[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；15 % 2-propanol, 10 % PEG4K, 0.1 M NaHEPES pH 8
|
Resolution 1.67 Å R-free 0.242 |
| 6SDD Crystal structure of D1228V cMET bound by BMS-777607 Deposited 2019-07-26 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1038–1346（309 aa）
|
Not recorded | 353 N-{4-[(2-amino-3-chloropyridin-4-yl)oxy]-3-fluorophenyl}-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide × 1 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；8 % ethanol, 20 % PEG8K, 0.1 M PCPT pH 7.5
|
Resolution 1.93 Å R-free 0.230 |
| 6SDE Crystal structure of wild-type cMET bound by savolitinib Deposited 2019-07-26 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1038–1346（309 aa）
|
Not recorded | V0L volitinib × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；15 % 2-propanol, 15 % PEG4K, 0.2 M PCPT pH 7.5
|
Resolution 2.49 Å R-free 0.273 |
| 6UBW MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF Antibody Deposited 2019-09-13 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1023–1360（338 aa）
Fragment：UNP residues 1023-1360
|
Not recorded | 84S N-(6-{difluoro[6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]methyl}imidazo[1,2-b]pyridazin-2-yl)cyclopropanecarboxamide × 1 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；12% isopropanol, 10% PEG5000 MME, 0.06 M HEPES sodium, 0.04 M HEPES
|
Resolution 2.00 Å R-free 0.225 |
| 6WVZ Crystal structure of anti-MET Fab arm of amivantamab in complex with human MET Deposited 2020-05-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 3 PDB declaration: trimeric |
Chain M
39–564（526 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 FMT FORMIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293.15 K；2.5M sodium formate, 5% PEG 400, 0.1M Tris pH 8.5
|
Resolution 3.10 Å R-free 0.235 |
| 7B3Q Crystal structure of c-MET bound by compound 1 Deposited 2020-12-01 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1049–1346（298 aa）
|
Not recorded | SV5 1-(phenylmethyl)-5~{H}-pyrrolo[3,2-c]pyridin-4-one × 1 SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；25 % PEG3350, 0.2 M (NH4)2SO4, 0.1 M Na-HEPES pH 7.5
|
Resolution 1.75 Å R-free 0.192 |
| 7B3T Crystal structure of c-MET bound by compound 2 Deposited 2020-12-01 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1049–1346（298 aa）
|
Not recorded | SVK 3-(phenylmethyl)-1~{H}-pyrrolo[2,3-b]pyridine × 1 CL CHLORIDE ION × 1 SO4 SULFATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；273 K；25 % PEG8000, 0.2 M Li2SO4
|
Resolution 2.23 Å R-free 0.261 |
| 7B3V Crystal structure of c-MET bound by compound 3 Deposited 2020-12-01 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1049–1346（298 aa）
|
Not recorded | SWB 3-(3-methyl-1~{H}-pyrrolo[2,3-b]pyridin-5-yl)-1~{H}-pyrrolo[3,4-b]pyrrol-6-one × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；273 K；25 % PEG3350, 0.2 M (NH4)2SO4, PCPT pH 5.5
|
Resolution 1.93 Å R-free 0.248 |
| 7B3W Crystal structure of c-MET bound by compound 4 Deposited 2020-12-01 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1049–1346（298 aa）
|
Not recorded | EDO 1,2-ETHANEDIOL × 1 SVH 3-(6-fluoranyl-1~{H}-indazol-4-yl)-4,5-dihydro-1~{H}-pyrrolo[3,4-b]pyrrol-6-one × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；8 % ethylene glycol, 10 % PEG8000, 0.1 M Na-HEPES pH 7.5
|
Resolution 2.02 Å R-free 0.261 |
| 7B3Z Crystal structure of c-MET bound by compound 5 Deposited 2020-12-01 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1049–1346（298 aa）
|
Not recorded | DMS DIMETHYL SULFOXIDE × 1 SV8 3-[3-(phenylmethyl)-1~{H}-pyrrolo[2,3-b]pyridin-5-yl]-4,5-dihydro-1~{H}-pyrrolo[3,4-b]pyrrol-6-one × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；20 % PEG10000, 0.1 M Na-HEPES pH 7.5
|
Resolution 1.80 Å R-free 0.215 |
| 7B40 Crystal structure of c-MET bound by compound 6 Deposited 2020-12-01 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1049–1346（298 aa）
|
Not recorded | SWN 3-(phenylmethyl)-5-(1-piperidin-4-ylpyrazol-4-yl)-1~{H}-pyrrolo[2,3-b]pyridine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；20 % PEG4000, 10 % isopropanol, 0.1 M Na-HEPES pH 7.5
|
Resolution 1.76 Å R-free 0.232 |
| 7B41 Crystal structure of c-MET bound by compound 7 Deposited 2020-12-02 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1049–1346（298 aa）
|
Not recorded | SWK 3-[(2-fluorophenyl)methyl]-5-(1-piperidin-4-ylpyrazol-4-yl)-1~{H}-pyrrolo[2,3-b]pyridine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；25 % PEG3350, 0.2 M MgCl2, 0.1 M bis-tris pH 5.5
|
Resolution 1.97 Å R-free 0.233 |
| 7B42 Crystal structure of c-MET bound by compound 8 Deposited 2020-12-02 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1049–1346（298 aa）
|
Not recorded | SW8 3-[(3-fluorophenyl)methyl]-5-(1-piperidin-4-ylpyrazol-4-yl)-1~{H}-pyrrolo[2,3-b]pyridine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；25 % PEG3350, 0.2 M MgCl2, 0.1 M bis-tris pH 6.5
|
Resolution 1.80 Å R-free 0.225 |
| 7B43 Crystal structure of c-MET bound by compound 9 Deposited 2020-12-02 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1049–1346（298 aa）
|
Not recorded | SW5 3-[(4-fluorophenyl)methyl]-5-(1-piperidin-4-ylpyrazol-4-yl)-1~{H}-pyrrolo[2,3-b]pyridine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；28 % PEGMME2000, 0.1 M bis-tris pH 6.5
|
Resolution 1.87 Å R-free 0.248 |
| 7B43 Crystal structure of c-MET bound by compound 9 Deposited 2020-12-02 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
1049–1346（298 aa）
|
Not recorded | SW5 3-[(4-fluorophenyl)methyl]-5-(1-piperidin-4-ylpyrazol-4-yl)-1~{H}-pyrrolo[2,3-b]pyridine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；28 % PEGMME2000, 0.1 M bis-tris pH 6.5
|
Resolution 1.87 Å R-free 0.248 |
| 7B44 Crystal structure of c-MET bound by compound S1 Deposited 2020-12-02 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1049–1346（298 aa）
|
Not recorded | SVT 5-methoxy-1~{H}-indazole × 1 DMS DIMETHYL SULFOXIDE × 2 SO4 SULFATE ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；25 % PEG3350, 0.2 M (NH4)2SO4, 0.1 M Na-HEPES pH 7.5
|
Resolution 1.76 Å R-free 0.208 |
| 7MO7 Cryo-EM structure of 2:2 c-MET/HGF holo-complex Deposited 2021-05-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain B
1–1390（1390 aa）
Chain E
1–1390（1390 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 4.80 Å |
| 7MO8 Cryo-EM structure of 1:1 c-MET I/HGF I complex after focused 3D refinement of holo-complex Deposited 2021-05-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
1–1390（1390 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 4.50 Å |
| 7MO9 Cryo-EM map of the c-MET II/HGF I/HGF II (K4 and SPH) sub-complex Deposited 2021-05-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 3 PDB declaration: trimeric |
Chain E
1–1390（1390 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 4.00 Å |
| 7MOA Cryo-EM structure of the c-MET II/HGF I complex bound with HGF II in a rigid conformation Deposited 2021-05-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 3 PDB declaration: trimeric |
Chain E
1–1390（1390 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 4.90 Å |
| 7MOB Cryo-EM structure of 2:2 c-MET/NK1 complex Deposited 2021-05-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain C
1–1390（1390 aa）
Chain D
1–1390（1390 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 5.00 Å |
| 7V3R Crystal structure of CMET in complex with a novel inhibitor Deposited 2021-08-11 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1038–1346（309 aa）
Fragment：UNP residues 1038-1346
|
Not recorded | 5IE ~{N}1'-[3-fluoranyl-4-(2-phenylazanylpyrimidin-4-yl)oxy-phenyl]-~{N}1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；0.1 M HEPES, 8% isopropanol, 3 mM TECP, 16% PEG4000, pH7.5
|
Resolution 1.70 Å R-free 0.190 |
| 7V3S Crystal structure of CMET in complex with a novel inhibitor Deposited 2021-08-11 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1038–1346（309 aa）
Fragment：UNP residues 1038-1346
|
Not recorded | 5I9 ~{N}1'-[3-fluoranyl-4-(10~{H}-pyrido[3,2-b][1,4]benzoxazin-4-yloxy)phenyl]-~{N}1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；0.1M HEPES, 8% isopropanol, 3mM TECP, 16% PEG4000, pH 7.5
|
Resolution 1.90 Å R-free 0.195 |
| 7Y4T Crystal structure of cMET kinase domain bound by compound 9I Deposited 2022-06-16 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1038–1346（309 aa）
Fragment：kinase domain
|
Not recorded | I90 2-[2-[3-(1-methylpyrazol-4-yl)quinolin-6-yl]ethyl]-6-(3-nitrophenyl)pyridazin-3-one × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；0.1 M HEPES (pH 7.8), 15-30% (v/v) PEG 8000
|
Resolution 2.16 Å R-free 0.251 |
| 7Y4U Crystal structure of cMET kinase domain bound by compound 9Y Deposited 2022-06-16 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1038–1346（309 aa）
Fragment：kinase domain
|
Not recorded | I94 ~{N}-methyl-4-[1-[2-[3-(1-methylpyrazol-4-yl)quinolin-6-yl]ethyl]-6-oxidanylidene-pyridazin-3-yl]-2-(trifluoromethyl)benzamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.8；291 K；0.1 M HEPES (pH 7.8), 15-30% (v/v) PEG 8000
|
Resolution 2.26 Å R-free 0.278 |
| 8AN8 Crystal structure of wild-type c-MET bound by compound 7. Deposited 2022-08-04 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1052–1346（295 aa）
|
Not recorded | SO4 SULFATE ION × 4 MDI 3-[bis(fluoranyl)methyl]-~{N}-methyl-~{N}-[(1~{R})-8-methyl-5-(3-methyl-1~{H}-indazol-6-yl)-1,2,3,4-tetrahydronaphthalen-1-yl]pyridine-2-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.4 M am sulfate, PCPT pH 5.5
|
Resolution 2.39 Å R-free 0.298 |
| 8AN8 Crystal structure of wild-type c-MET bound by compound 7. Deposited 2022-08-04 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
1052–1346（295 aa）
|
Not recorded | SO4 SULFATE ION × 1 MDI 3-[bis(fluoranyl)methyl]-~{N}-methyl-~{N}-[(1~{R})-8-methyl-5-(3-methyl-1~{H}-indazol-6-yl)-1,2,3,4-tetrahydronaphthalen-1-yl]pyridine-2-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.4 M am sulfate, PCPT pH 5.5
|
Resolution 2.39 Å R-free 0.298 |
| 8ANS Crystal structure of D1228V c-MET bound by compound 1. Deposited 2022-08-05 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1052–1346（295 aa）
|
Mutation：D1228V | GOL GLYCEROL × 1 MDI 3-[bis(fluoranyl)methyl]-~{N}-methyl-~{N}-[(1~{R})-8-methyl-5-(3-methyl-1~{H}-indazol-6-yl)-1,2,3,4-tetrahydronaphthalen-1-yl]pyridine-2-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；15 % PEG10K, 100 mM PCPT pH 7.5
|
Resolution 2.01 Å R-free 0.277 |
| 8AU3 c-MET Y1234E,Y1235E mutant in complex with Tepotinib Deposited 2022-08-25 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1051–1349（299 aa）
|
Not recorded | 3E8 3-[1-(3-{5-[(1-methylpiperidin-4-yl)methoxy]pyrimidin-2-yl}benzyl)-6-oxo-1,6-dihydropyridazin-3-yl]benzonitrile × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；293 K；3.4 M NaFormiate, 0.1 M MES
|
Resolution 2.26 Å R-free 0.240 |
| 8AU3 c-MET Y1234E,Y1235E mutant in complex with Tepotinib Deposited 2022-08-25 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
1051–1349（299 aa）
|
Not recorded | 3E8 3-[1-(3-{5-[(1-methylpiperidin-4-yl)methoxy]pyrimidin-2-yl}benzyl)-6-oxo-1,6-dihydropyridazin-3-yl]benzonitrile × 1 PG4 TETRAETHYLENE GLYCOL × 1 PEG DI(HYDROXYETHYL)ETHER × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；293 K；3.4 M NaFormiate, 0.1 M MES
|
Resolution 2.26 Å R-free 0.240 |
| 8AU5 c-MET F1200I mutant in complex with Tepotinib Deposited 2022-08-25 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1051–1349（299 aa）
Fragment：KINASE DOMAIN
|
Not recorded | 3E8 3-[1-(3-{5-[(1-methylpiperidin-4-yl)methoxy]pyrimidin-2-yl}benzyl)-6-oxo-1,6-dihydropyridazin-3-yl]benzonitrile × 1 EDO 1,2-ETHANEDIOL × 3 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7.6；293 K；PEG 8000
|
Resolution 2.72 Å R-free 0.278 |
| 8AW1 c-MET Y1235D mutant in complex with Tepotinib Deposited 2022-08-29 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1051–1349（299 aa）
Fragment：KINASE DOMAIN
|
Not recorded | 3E8 3-[1-(3-{5-[(1-methylpiperidin-4-yl)methoxy]pyrimidin-2-yl}benzyl)-6-oxo-1,6-dihydropyridazin-3-yl]benzonitrile × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；298 K；PEG 8,000
|
Resolution 2.14 Å R-free 0.241 |
| 8AW1 c-MET Y1235D mutant in complex with Tepotinib Deposited 2022-08-29 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
1051–1349（299 aa）
Fragment：KINASE DOMAIN
|
Not recorded | 3E8 3-[1-(3-{5-[(1-methylpiperidin-4-yl)methoxy]pyrimidin-2-yl}benzyl)-6-oxo-1,6-dihydropyridazin-3-yl]benzonitrile × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；298 K；PEG 8,000
|
Resolution 2.14 Å R-free 0.241 |
| 8GVJ Crystal structure of cMET kinase domain bound by D6808 Deposited 2022-09-15 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1038–1346（309 aa）
Fragment：kinase domain
|
Not recorded | KGL (1^4Z,5^2E)-6^3-(trifluoromethyl)-5^1,5^6-dihydro-1^1H-8-aza-2(3,6)-quinolina-5(1,3)-pyridazina-1(4,1)-pyrazola-6(1,4)-benzenacyclododecaphane-5^6,7-dione × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；25% PEG 8K
|
Resolution 2.71 Å R-free 0.262 |
| 8K78 Crystal structure of cMET kinase domain bound by TPX-0022 Deposited 2023-07-26 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1038–1346（309 aa）
|
Not recorded | IYC Elzovantinib × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；25% PEG 8K
|
Resolution 2.67 Å R-free 0.290 |
| 8OUU Crystal structure of D1228V c-MET bound by compound 29 Deposited 2023-04-24 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1038–1346（309 aa）
|
Mutation：D1228V | GOL GLYCEROL × 1 EDO 1,2-ETHANEDIOL × 1 FMT FORMIC ACID × 1 W49 5-(3-ethynyl-5-fluoranyl-1H-indazol-7-yl)-1-[(1S)-1-phenylethyl]pyrimidine-2,4-dione × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；2 M Na formate, 0.1 M Na acetate pH 4.6
|
Resolution 1.77 Å R-free 0.225 |
| 8OUU Crystal structure of D1228V c-MET bound by compound 29 Deposited 2023-04-24 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
1038–1346（309 aa）
|
Mutation：D1228V | EDO 1,2-ETHANEDIOL × 2 FMT FORMIC ACID × 2 W49 5-(3-ethynyl-5-fluoranyl-1H-indazol-7-yl)-1-[(1S)-1-phenylethyl]pyrimidine-2,4-dione × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；2 M Na formate, 0.1 M Na acetate pH 4.6
|
Resolution 1.77 Å R-free 0.225 |
| 8OUV Crystal structure of D1228V c-MET bound by compound 15 Deposited 2023-04-24 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1038–1346（309 aa）
|
Mutation：D1228V | W3R 5-(1H-indazol-7-yl)-1-[(1S)-1-phenylethyl]pyrimidine-2,4-dione × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；293 K；30 % PEG400, 0.1 M CaCl2, 0.1 M PCPT pH 4.5.
|
Resolution 1.78 Å R-free 0.220 |
| 8OUV Crystal structure of D1228V c-MET bound by compound 15 Deposited 2023-04-24 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
1038–1346（309 aa）
|
Mutation：D1228V | W3R 5-(1H-indazol-7-yl)-1-[(1S)-1-phenylethyl]pyrimidine-2,4-dione × 1 CL CHLORIDE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；293 K；30 % PEG400, 0.1 M CaCl2, 0.1 M PCPT pH 4.5.
|
Resolution 1.78 Å R-free 0.220 |
| 8OV7 Crystal structure of D1228V c-MET bound by compound 10 Deposited 2023-04-25 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1038–1346（309 aa）
|
Mutation：D1228V | W3W 5-[3,5-bis(fluoranyl)phenyl]-1-[(1S)-1-[3-(1H-imidazol-5-yl)phenyl]ethyl]pyrimidine-2,4-dione × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；293 K；1.5 M LiCl, 0.1 M Na HEPES pH 7.5
|
Resolution 1.95 Å R-free 0.287 |
| 8OVZ Crystal structure of D1228V c-MET bound by compound 16 Deposited 2023-04-26 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1038–1346（309 aa）
|
Mutation：D1228V | IOD IODIDE ION × 10 W3N 1-[(1S)-1-[3-(1H-imidazol-4-yl)phenyl]ethyl]-5-(1H-indazol-7-yl)pyrimidine-2,4-dione × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；12 % PEG 8000, 200 mM NH4I, 0.1 M PCPT pH 7
|
Resolution 2.21 Å R-free 0.275 |
| 8OVZ Crystal structure of D1228V c-MET bound by compound 16 Deposited 2023-04-26 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
1038–1346（309 aa）
|
Mutation：D1228V | IOD IODIDE ION × 9 W3N 1-[(1S)-1-[3-(1H-imidazol-4-yl)phenyl]ethyl]-5-(1H-indazol-7-yl)pyrimidine-2,4-dione × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；12 % PEG 8000, 200 mM NH4I, 0.1 M PCPT pH 7
|
Resolution 2.21 Å R-free 0.275 |
| 8OW3 Crystal structure of wild-type c-MET bound by compound 2 Deposited 2023-04-26 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1038–1346（309 aa）
|
Not recorded | W40 5-[3,5-bis(fluoranyl)phenyl]-1-[(1S)-1-phenylethyl]pyrimidine-2,4-dione × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；12 % PEG3350, 5 % EtOH, 0.2 M Li2SO4, 100 mM PCPT pH 5
|
Resolution 2.27 Å R-free 0.295 |
| 8OWG Crystal structure of D1228V c-MET bound by compound 2 Deposited 2023-04-27 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1038–1346（309 aa）
|
Mutation：D1228V | W40 5-[3,5-bis(fluoranyl)phenyl]-1-[(1S)-1-phenylethyl]pyrimidine-2,4-dione × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；15 % PEG2000 MME, 0.1 M PCPT pH 6.5
|
Resolution 2.63 Å R-free 0.329 |
| 8OWG Crystal structure of D1228V c-MET bound by compound 2 Deposited 2023-04-27 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
1038–1346（309 aa）
|
Mutation：D1228V | W40 5-[3,5-bis(fluoranyl)phenyl]-1-[(1S)-1-phenylethyl]pyrimidine-2,4-dione × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；15 % PEG2000 MME, 0.1 M PCPT pH 6.5
|
Resolution 2.63 Å R-free 0.329 |
| 8OWG Crystal structure of D1228V c-MET bound by compound 2 Deposited 2023-04-27 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain C
1038–1346（309 aa）
|
Mutation：D1228V | W40 5-[3,5-bis(fluoranyl)phenyl]-1-[(1S)-1-phenylethyl]pyrimidine-2,4-dione × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；15 % PEG2000 MME, 0.1 M PCPT pH 6.5
|
Resolution 2.63 Å R-free 0.329 |
| 8VI1 Crystal structure of c-Met-D1228N in complex with KIN-7615 Deposited 2024-01-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
1038–1346（309 aa）
Chain B
1038–1346（309 aa）
|
Not recorded | A1AB1 N-(3,5-difluoro-4-{[6-(2-hydroxyethoxy)-7-methoxyquinolin-4-yl]oxy}phenyl)-4-methoxypyridine-3-carboxamide × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；0.1M HEPES pH7.5, 12.5% PEG4000, 10% isopropanol
|
Resolution 3.11 Å R-free 0.298 |
| 9C1R Crystal structure of mutant cMET D1228N kinase domain in complex with inhibitor compound 13 Deposited 2024-05-29 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1048–1348（301 aa）
Fragment：UNP Residues 1048-1348
|
Mutation：D1228N | GOL GLYCEROL × 1 A1ATS N-(2,5-difluoro-4-{[(1s,3S)-3-(1-methyl-1H-pyrazol-3-yl)cyclobutyl][(8R)-pyrazolo[1,5-a]pyrazin-4-yl]amino}phenyl)-2-(5-fluoropyridin-2-yl)-3-oxo-2,3-dihydropyridazine-4-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；22% PEG 3350
0.1M Bis-Tris pH6.5
|
Resolution 1.59 Å R-free 0.195 |
| 9IVB Crystal structure of c-Met kinase domain bound by bozitinib Deposited 2024-07-23 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1038–1346（309 aa）
Fragment：kinase domain
|
Not recorded | A1L3A bozitinib × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.8；291 K；15-30% PEG8K
|
Resolution 2.35 Å R-free 0.273 |
| 9IVB Crystal structure of c-Met kinase domain bound by bozitinib Deposited 2024-07-23 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
1038–1346（309 aa）
Fragment：kinase domain
|
Not recorded | A1L3A bozitinib × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.8；291 K；15-30% PEG8K
|
Resolution 2.35 Å R-free 0.273 |
| 9SXJ Crystal structure of wild-type c-MET bound by capmatinib. Deposited 2025-10-09 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1052–1346（295 aa）
|
Not recorded | A1JRF Capmatinib × 1 12P DODECAETHYLENE GLYCOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；30% PEG3350, 0.2 M MgCl2,
0.1 M PCTP pH 7.5
|
Resolution 1.31 Å R-free 0.231 |
| 9SZJ Crystal structure of Y1230H c-MET bound by capmatinib. Deposited 2025-10-14 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1038–1346（309 aa）
|
Not recorded | A1JRF Capmatinib × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；Morpheus HT-96 (MD1-47) condition D10
|
Resolution 2.29 Å R-free 0.304 |
| 9T08 Crystal structure of wild-type c-MET bound by sitravatinib. Deposited 2025-10-16 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1052–1346（295 aa）
|
Not recorded | A1JSO Sitravatinib × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；20% PEG4K, 10% isopropanol, 0.1 M Na-HEPES pH 7.5
|
Resolution 1.46 Å R-free 0.242 |
| 9T0B Crystal structure of D1228V c-MET bound by sitravatinib. Deposited 2025-10-16 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1038–1346（309 aa）
|
Not recorded | A1JSO Sitravatinib × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；25% PEG3350, 0.2 M Na OAc, 0.1 M PCTP pH 6.0
|
Resolution 1.54 Å R-free 0.294 |
| 9T0D Crystal structure of wild-type c-MET bound by glesatinib Deposited 2025-10-16 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1052–1346（295 aa）
|
Not recorded | A1JSR Glesatinib × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；30% PEG8K, 0.2 M NaOAc,
0.1 M Na cacodylate pH 6.5
|
Resolution 1.20 Å R-free 0.221 |
| 9T1Q Crystal structure of D1228V c-MET bound by glesatinib. Deposited 2025-10-21 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1038–1346（309 aa）
|
Mutation：D1228V | A1JSR Glesatinib × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；25% PEG3350, 0.2 M Na formate, 0.1 M PCTP pH 8.0
|
Resolution 1.94 Å R-free 0.270 |
| 9T2V Crystal structure of wild-type c-MET bound by cabozantinib. Deposited 2025-10-23 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1052–1346（295 aa）
|
Not recorded | A1JS8 Cabozantinib × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；20% PEG4K, 10% isopropanol, 0.1 M Na-HEPES pH 7.5
|
Resolution 1.67 Å R-free 0.226 |
| 9T3Q Crystal structure of D1228V c-MET bound by cabozantinib. Deposited 2025-10-28 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1038–1346（309 aa）
|
Not recorded | A1JS8 Cabozantinib × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；20% PEG4K, 10% isopropanol,
0.1 M Na-HEPES pH 7.5
|
Resolution 1.63 Å R-free 0.238 |
| 9T6K Crystal structure of wild-type c-MET bound by glumetinib. Deposited 2025-11-07 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1052–1346（295 aa）
|
Not recorded | A1JT6 Glumetinib × 1 15P POLYETHYLENE GLYCOL (N=34) × 2 PEG DI(HYDROXYETHYL)ETHER × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；30% PEG400,
0.1 M PCTP pH 8.5
|
Resolution 1.13 Å R-free 0.197 |
128 other PDB entries and 166 assemblies. Open the comparison page and filter oligomeric states
View Construct and Data Evidence
| UniProt name | MET_HUMAN |
| Isoform | — |
| PDB entities | 1 |
| Chains and sequence ranges | Author chain A； PDBConstruct 8–319； UniProt 1049–1360 |
